SOURCE: Proteonomix

Proteonomix

February 25, 2010 08:30 ET

Proteonomix, Inc. (PROT) Announces the Appointment of Ashoke Agarwal, M.D. as Chief Scientific Officer of Its Subsidiary, Stromacel, Inc.

MOUNTAINSIDE, NJ--(Marketwire - February 25, 2010) -  Proteonomix, Inc. (PINKSHEETS: PROT) announces the appointment of Ashoke Agarwal, M.D., F.A.C.C. as Chief Scientific Officer of its subsidiary, StromaCel, Inc.

Dr. Agarwal, 62 years old, is also Chief Scientific Officer for the Company's subsidiary, National Stem Cell, Inc. He has been in private practice in the fields of Internal Medicine and Cardiology since 1983 and is affiliated with four hospitals in New Jersey. He was formerly Chairman of the Department of Medicine (1996-1998) and Section Chief of the Department of Cardiology (1999 - 2002) at Barnert Hospital, Paterson, New Jersey. He also served as Section Chief, Division of Cardiology at Passaic Beth Israel Hospital (1994 - 1996). He is a member of a number of medical societies and committees including the New Jersey State Medical Society (since 1984). Dr. Agarwal is past president of the Passaic County Medical Society. He received his medical degree at the Medical College, Calcutta, India, in 1969.

Dr. Agarwal is a member of the American College of Cardiology and a Fellow of the American College of Cardiology (F.A.C.C.), a leading professional society representing heart specialists in the United States and abroad. Members of the F.A.C.C. include adult cardiologists, pediatric cardiologists, cardiovascular surgeons, researchers and academicians, and specialists in a cardiovascular-related field. Dr. Agarwal is certified in Internal Medicine by the American Board of Internal Medicine.

Michael Cohen, President of Proteonomix, stated: "Dr. Agarwal has served as Chief Scientific Officer of our subsidiary, National Stem Cell, Inc. and has contributed to our research into stem cell therapies for cardiac disease. We welcome his talents and knowledge to guide the development of therapies in StromaCel, Inc., our new subsidiary."

Dr. Agarwal stated: "I look forward to integrating my professional expertise and background with the development of regenerative medicine planned to be developed by StromaCel."

StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit www.proteonomix.com, www.proteoderm.com, www.pinksheets.com and www.sec.gov for further information about Proteonomix.

Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at time the statements are made.

Contact Information

  • Contact:
    Michael Cohen
    Proteonomix, Inc.
    (973) 544-6116